Showing 731-740 of 1321 results for "".
- Happy 25th Birthday Restylane!https://practicaldermatology.com/news/happy-25th-birthday-restylane/2460928/Galderma’s Restylane is celebrating 25 years on the market. Since launching in Europe in 1996, Restylane has celebrated many milestones across the globe. This includes the first approval for use by the U.S. Food and Drug Administration (FDA) in 2003 and in China by the
- Galderma and Cetaphil Announce New Clear Skies Initiativehttps://practicaldermatology.com/news/galderma-and-cetaphil-announce-new-clear-skies-initiative/2460927/Galderma and Cetaphil are proud to announce the Clear Skies initiative, a long-term commitment to supporting a healthier environment. Galderma has made great strides to reduce its environmental footprint over the past decade, and Clear Skies outlines the company's journey
- Cetaphil Updates Formulas, Launches 16 New Productshttps://practicaldermatology.com/news/cetaphil-updates-formulas-launches-16-new-products/2460922/Cetaphil is updating their formulas and launching 16 new products including their first-ever acne care line. The brand’s most prominent products have been upgraded to feature a blend of Niacinamide (Vitamin B3), Panthenol (Vitamin B5), and hydrating Glycerin to improve skin’
- Dr. Eugene A. Bauer Joins American Skin Association Boardhttps://practicaldermatology.com/news/dr-eugene-a-bauer-joins-american-skin-association-board/2460915/Eugene Bauer, MD, will join the American Skin Association’s (ASA) Board of Directors. Dr. Bauer is Professor, Emeritus, at Stanford University School of Medicine. He is immediate past co-founder, Chief Medical Officer, and member of the Board of Directors of Dermir
- New Publication Supports Diagnostic Value of DermTech's PLAhttps://practicaldermatology.com/news/new-publication-supports-diagnostic-value-of-dermtechs-pla/2460914/Evaluation of genomic atypia with DermTech’s Pigmented Lesion Assay (PLA) increases both the real-world negative predictive value (NPV) and positive predictive value (PPV) of the melanoma diagnostic pathway and reduces biopsy burden, relative to the current visual assessment and histopathol
- AbbVie, BTL Settle Patent Disputehttps://practicaldermatology.com/news/abbvie-btl-settle-patent-dispute/2460906/BTL Industries has resolved its patent infringement claims against AbbVie related to BTL's muscle stimulation technology. Under the terms of the settlement agreement, AbbVie will pay BTL an undisclosed payment. The details of the agreement are confidential and will not be disc
- Study: UV Exposure Produces Epigenetic Changes in the Epidermis to Induce Skin Pigmentationhttps://practicaldermatology.com/news/study-uv-exposure-produces-epigenetic-changes-in-the-epidermis-to-induce-skin-pigmentation/2460905/Exposure to the sun's ultraviolet (UV) rays produces epigenetic changes in the epidermis to induce skin pigmentation, a new study shows. UV exposure causes DNA damage in epidermal cells and is a leading cause of skin cancers. To protect from the damaging effects of UV exposure, epid
- European Commission Approves UCB's BIMZELX for Adults with Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/european-commission-approves-ucbs-bimzelx-for-adults-with-moderate-to-severe-plaque-psoriasis/2460895/The European Commission (EC) has granted marketing authorization for UCB's bimekizumab (Bimzelx) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Bimekizumab is the first approved treatment in the European Union (EU) for moderate
- First Patient Dosed in Kinnate's Phase 1 trial of KIN-2787 in Patients with BRAF Mutation-Positive Solid Tumorshttps://practicaldermatology.com/news/first-patient-dosed-in-kinnates-phase-1-trial-of-kin-2787-in-patients-with-braf-mutation-positive-solid-tumors/2460894/The first patient has commenced treatment in Kinnate Biopharma Inc.’s Phase 1 KN-8701 trial of its lead RAF product candidate, KIN-2787, a pan-RAF inhibitor being developed for the treatment of patients with melanoma, lung cancer, and other solid tumors. While three kina
- Lilly's Lebrikizumab Performs Well in Two Phase 3 AD Trialshttps://practicaldermatology.com/news/lillys-lebrikizumab-performs-well-in-two-phase-3-ad-trials/2460892/Eli Lilly and Company's lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), according to top-line results from ADvocate 1 and ADvocate 2. All primary and all key secondary en